Patient Prefer Adher
-
Patient Prefer Adher · Jan 2024
Hierarchical Medical: What are the Factors Driving ESKD Patients to Choose Community Hemodialysis Centers in China? A Labelled Discrete Choice Experiment.
In China, secondary and tertiary hospital-based dialysis facilities had been the most prominent provider of hemodialysis treatment. Developing community hemodialysis centers was the key to constructing hierarchical hemodialysis system. Thus, the aim of this study was to explore end-stage kidney disease (ESKD) patients' preferences for hemodialysis services and attract patients with stable condition to choose community hemodialysis services. ⋯ A better understanding of ESKD patients' preferences for hemodialysis service is a crucial step for the future policy implementations. Although patients tended to choose hospital-based hemodialysis facilities, patients' preferences for hemodialysis institutions would reverse with the change of service attribute. Establishing a smooth and effective referral is the most important attribute to improve patients' acceptance of community hemodialysis centers. Strengthening the integration of service can facilitate hierarchical hemodialysis service system.
-
Patient Prefer Adher · Jan 2024
Flu Vaccination Among Patients with Noncommunicable Diseases: A Survey About Awareness, Usage, Gaps and Barriers in Europe.
People with noncommunicable diseases (NCDs) have a high risk of contracting flu and suffering from its associated complications; however, in many countries flu vaccine uptake in this group is sub-optimal. This survey assessed the knowledge, attitudes, and gaps toward vaccination in general and flu in particular among adults with NCDs in Europe. ⋯ Healthcare practitioners are the key influencers for people to get vaccinated. The dissemination of information about the importance of flu vaccines needs to be increased, and clear and explanatory messaging based on country-specific characteristics is important.
-
Patient Prefer Adher · Jan 2024
ReviewThe Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects.
Obesity is becoming more frequent and has several negative health impacts. Recent advances in weight management strategies have primarily resided in pharmaceutical treatments, and the glucagon-like peptide-1 (GLP-1) receptor agonists have shown great potential in terms of body weight reduction in addition to improving glycemic control in patients with type 2 diabetes (T2D). Recently, the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has been developed. ⋯ Overall, discontinuation due to adverse events occurred in 3-7% of participants with no major differences between individuals with and without T2D. The higher weight-reducing efficacy of tirzepatide in trial participants without T2D is currently unexplained and may be partly reflected in dissimilarities in frequencies of gastrointestinal adverse events. The weight reducing effects of tirzepatide hold great promise for weight management in obese patients regardless of the presence of T2D.